Drug sponsors could soon learn what data FDA considers sufficient to support a labeling claim of abuse-deterrence for an opioid drug.
The agency has received inquiries about specific products and “whether the agency believes that those products are, in fact, abuse-deterrent,”...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?